Currently, the development of partial PPARγ agonists is underway in the hopes that unlike TZDs which are full PPARγ agonists, selective partial agonists will be associated with lesser adverse effects such as fluid retention, heart failure, and so forth while retaining the insulin sensitizing effects. The gene discussed is INS; the disease is heart failure.